艾迪注射液联合GO方案治疗晚期非小细胞肺癌  

Clinical Research of Aidi Injection Combined with GO in Treating Advanced Non-small-cell Lung Cancer

作　　者：李海金[1] 董良[1] 李英[1] 符淑媛[2] 

机构地区：[1]中国医科大学绍兴华宇医院肿瘤内科,绍兴312030 [2]锦州医学院附属医院肿瘤外科

出　　处：《浙江中西医结合杂志》2008年第8期473-475,共3页Zhejiang Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:观察艾迪注射液联合GO方案(吉西他滨加奥沙利铂)治疗晚期非小细胞肺癌的近期疗效和不良反应。方法:104例非小细胞肺癌随机分治疗组53例,予艾迪注射液60ml加入5%葡萄糖注射液250ml中静脉滴注,1天1次,连用10天;GO方案用法:吉西他滨1000mg/m2,静脉滴注,第1、8天;奥沙利铂135mg/m2,静脉滴注,第1天;21天为1个周期。对照组51例,单用GO方案化疗,21天为1个周期。分别观察两组近期疗效、生活质量、不良反应、NK细胞和T淋巴细胞变化及生存期。结果:治疗组和对照组有效率分别为54.72%、47.06%,两组比较,P>0.05;生活质量分别提高58.49%、23.53%,两组比较,P<0.05。不良反应治疗组明显小于对照组(P<0.05);治疗组治疗后NK细胞活性及CD4+/CD8+比值明显高于治疗前和对照组(P<0.05);治疗组1年生存率58.49%,对照组45.10%,两组比较,P>0.05。结论:艾迪注射液联合GO方案治疗晚期非小细胞肺癌疗效肯定,生活质量改善,不良反应减轻,机体免疫功能提高,生存期延长。Objective：To observe the short term curative effect and side effect of Aid injection combined with gemcitabine and oxaliplatin regimen （GO） in treating advanced non-small-cell lung cancer （NSCLC）. Methods： 104 cases of NSCLC were randomly divided into the treatment group （53 cases） and the contrast group （51 cases ）. The contrast group was treated only by GO regimen, which was combined with 100mg/m^2 Gemcitabine on the first day and the eighth day and 135mg/ m^2 Oxaliplatin on the first day. The treatment group was added by 250 ml 5% glucose with 50 ml Aid injection each day for 10 days on the base of GO regimen. The period of therapy was 21 days. The short term curative effect, life quality, side effect, changes of NK cells and T-lymphocyte sub-group, the survival time of the two groups were observed and compared. Results：The effective ratio of the treatment group and the contrast group was 54.72% and 47.06% respectively （P 〉 0.05 ）. The improvement ratio llfe quality of the treatment group and the contrast group was 58.49% and 23.53% respectively （ P 〈 0.05 ）. The side effect of the treatment group was significantly less than that of the contrast group （ P 〈 0.05 ）. The activity of NK and the ratio of CD^4 ＋/ CD8^＋ of the treatment group after therapy was obviously higher than that of the treatment group before therapy and the contrast group （ P 〈 0.05 ）. The one-year survival ratio of the treatment group and the contrast group was 58.49% and 45.1% respectively （ P 〉 0.05 ）. Conclusion： Aidi injection combined with GO regimen has certain curative effect on treating advanced NSCLC by reducing the side effect, improving life quality and immune function, and prolonging the survival time.

关 键 词：非小细胞肺癌 艾迪注射液 吉西他滨 奥沙利铂 不良反应 

分 类 号：R734.2[医药卫生—肿瘤] R521[医药卫生—临床医学]